Developmental Therapeutics at NU
Research Center and Core Facility
From Research to Treatment
Academic-Based Drug Development
The Developmental Therapeutics Core (DTC), under the umbrella of CDT, provides services focused on supporting the translation of new therapeutics to the clinic. See services offered here.
From Bench to Bedside
Since its founding, the Center has facilitated the completion of IND-enabling studies for a homegrown, trial-ready drug to treat acute myeloid leukemia, pre-IND, Phase 0 trials for both Au-NP spherical nucleic acids and apoptosis targeting projects, proof-of concept work for the GSK-3β inhibitor 9 ING-41, and the design and characterization of novel peptides that mimic the function of natural inhibitors of the blood vessel growth (angiogenesis) that cause age-related macular degeneration (AMD).
Monitoring blood oxygen saturation via implantable devices
DTC works with PI Sui Huang to develop a new compound, metarrestin, to reduce metastasis by human prostate, pacreatic, and breast cancer.